[ad_1]
Researchers suspect that a new strain of refractory gonorrhea has been detected in Austria and treatment for sexually transmitted diseases has failed.
“Worry, this is the second strain of the Asian gonococcal genome substrain,” the author writes. April study It was published in Eurosurveillance. “Enhanced resistance monitoring and action are essential to prevent spread.”
The new gonorrhea strain detected was defined as a wide range of drug-resistant strains resistant to both ceftriaxone and azithromycin, a recommended combination of treatments to prevent the development of antibiotic resistance.
Further testing of this strain revealed that it was also resistant to all the antibiotics used to treat gonorrhea: cefixime, cefotaxime, ciprofloxacin, and tetracycline.
However, subsequent clinical trials found that the bacterial strain was sensitive to two prescription antibiotics, spectinomycin and high-dose penicillin. Two antibiotics still in clinical trials.
A sick male heterosexual patient developed it in Cambodia through unprotected sex with a sex worker. Five days after contraction, he reported painful urination and urethral secretions.
The patient reported that he was asymptomatic two weeks after treatment with ceftriaxone and azithromycin and had negative urethral, rectal, and pharyngeal tests. However, the researchers suspect that the treatment has failed because the PCR test returned positive.
Researchers have shown biological resistance to both ceftriaxone and azithromycin in the second strain identified as the recommended dual treatment to reduce antibiotic resistance. Given that, he emphasized that the results of this study are of concern.
2016, Britain reported first failure The first case of a gonorrhea strain resistant to both ceftriaxone and azithromycin has been reported in the United Kingdom in the treatment of gonorrhea with ceftriaxone and azithromycin, and by 2018, after the patient had gonorrhea in Southeast Asia. rice field.
Subsequent cases of the same strain were also detected in Spain, France, Australia, and Japan.
The authors write that a wide range of drug-resistant N. gonorrhoeae strains, including resistance to all available treatments, are “a major public health concern in the world.”
“They pose a risk of treatment failure and serious complications at the individual level, but jeopardize the management and control of gonorrhea at the public health level.”
According to the Centers for Disease Control and Prevention (CDC), gonorrhea is currently the second most commonly reported bacterial infection in the United States.
More than 500,000 cases of gonorrhea are reported annually. Nevertheless, the CDC estimates that 1.6 million new infections can actually occur each year, with half of all infections being resistant to at least one antibiotic each year.
Antibiotic-resistant gonorrhea is a major public health concern.based on CDC website, “Currently, we are using cephalosporins, the last recommended and effective class of antibiotics, to treat this common infection.”
“This is an urgent public health threat, as gonorrhea control in the United States relies heavily on its ability to successfully treat infectious diseases.”
Gonorrhea is a sexually transmitted disease that can only be transmitted by sexual contact. It affects both men and women, primarily the urethra, rectum, or throat. In women, the cervix can also be infected.
Infected mothers’ babies can also become infected during childbirth. In babies, the disease most commonly affects the eyes.
If untreated, the disease may increase the risk of becoming infected with HIV, the virus that causes AIDS. Untreated gonorrhea can also spread to the blood and cause disseminated infections, which can be life-threatening.
So far, there have been no validated reports of failure in clinical treatment with cephalosporins for this infection in the United States.
[ad_2]